Immune-activating recombinant oncolytic virus and use thereof

By inserting HBsAg, IL-15, and IL-15Ra sequences into recombinant oncolytic viruses, the immune response of HBV-positive tumor cells is activated, solving the problems of drug resistance and high recurrence rate in HBV-positive liver cancer patients, and achieving a treatment effect with high cure rate and low recurrence rate.

WO2026123644A1 Publication Date: 2026-06-18WUHAN UNIV
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
WUHAN UNIV
Filing Date
2025-06-26
Publication Date
2026-06-18

AI Technical Summary

⚠Technical Problem

HBV-positive liver cancer patients have drug resistance issues during immunotherapy, and the recurrence rate of liver cancer is high. Existing oncolytic virus therapy is difficult to effectively activate the host's anti-tumor immune response and prevent tumor recurrence.

⚗Method used

Nucleotide sequences encoding HBsAg, IL-15, and IL-15Ra are inserted into the genome of an immune-activated recombinant oncolytic virus. By infecting HBV-positive tumor cells, this activates the anti-tumor immune response, expresses HBV surface antigens and cytokines, enhances the function of T cells and NK cells, and prevents tumor recurrence.

🎯Benefits of technology

It improved the tumor cure rate, reduced the tumor recurrence rate, significantly inhibited tumor growth, prolonged the survival of tumor-bearing mice, and prevented tumor recurrence by activating specific T cell responses and enhancing immune memory.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
Patent Text Reader

Abstract

Disclosed in the present application are an immune-activating recombinant oncolytic virus and use thereof, relating to the field of biomedicine. A genome of the immune-activating recombinant oncolytic virus comprises a first nucleotide sequence for encoding an HBsAg molecule, a second nucleotide sequence for encoding an IL-15 molecule, and a third nucleotide sequence for encoding a sushi domain of IL-15Ra. According to the present application, by inserting the first nucleotide sequence for encoding the HBsAg molecule, the second nucleotide sequence for encoding the IL-15 molecule, and the third nucleotide sequence for encoding the sushi domain of IL-15Ra into the genome of the immune-activating recombinant oncolytic virus, the cure rate of tumors is improved while tumor recurrence is prevented.
Need to check novelty before this filing date? Find Prior Art